Lates News

Every AI Express of Morning Post, SDIC Securities released a research report on January 19, giving Kanghong Pharmaceutical (002773.SZ) a "buy" rating. The main reasons for the rating include: 1) Leading in innovative ophthalmic drugs, opening up long-term growth space with innovative pipeline; 2) The blue ocean market of ophthalmic diseases worth billions, Kangbexipu is growing rapidly; 3) The ophthalmic gene therapy industry is entering a window period, and the global competition is entering the fierce second half; 4) The innovative pipeline is gradually forming, and the domestic progress in gene therapy is leading. (Daily Economic News)